Baseline demographic and clinical characteristics (all enrolled population)
| 28-day TIS (n=45) | 56-day TIS (n=43) | |
| Mean (SD) age (years) | 8.7 (7.2) | 8.7 (10.5) |
| Age group, n (%) | ||
| 6 months–<6 years | 19 (42) | 18 (42) |
| 6–<18 years | 20 (44) | 21 (49) |
| ≥18 years | 6 (13) | 4 (9) |
| Gender, n (%) | ||
| Female | 19 (42) | 21 (49) |
| Male | 26 (58) | 22 (51) |
| Mean (SD) weight (kg) | 30.0 (19.8) | 27.4 (17.3) |
| Mean (SD) height (cm) | 124.8 (34.3) | 121.9 (31.7) |
| Previously vaccinated against Pa, n (%) | 2 (4) | 7 (16) |
| Cystic fibrosis genotype, n (%) | ||
| F508/F508 | 17 (38) | 21 (49) |
| F508/other | 19 (42) | 14 (33) |
| Other/other | 5 (11) | 4 (9) |
| Unknown/not available | 4 (9) | 4 (9) |
| Infection with Pa, n (%) | ||
| First | 28 (62) | 27 (63) |
| Early, after 1 year negative culture | 8 (18) | 8 (19) |
| Early, after 2 years negative culture | 8 (18) | 8 (19) |
| Not available | 1 (2) | 0 (0) |
| Pulmonary function tests, mean (SD) | ||
| FEV1 % predicted | 80.2 (18.9) | 87.0 (19.2) |
| FVC % predicted | 91.1 (15.3) | 99.2 (20.2) |
| FEF25–75 % predicted | 61.5 (28.8) | 63.4 (26.9) |
FEF25–75, forced expiratory flow between 25% and 75%; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; Pa, Pseudomonas aeruginosa; TIS, tobramycin inhalation solution 300 mg/5 ml.